Last reviewed · How we verify
NCT06180577
A Survey Study to Assess the Accessibility of the Nerivio Device At School
trial testing Nerivio in Migraine in Children in 332 participants. Completed in 15 May 2024.
1 May 2024
Quick facts
| Lead sponsor | Theranica |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 332 |
| Start date | 1 February 2024 |
| Primary completion | 1 May 2024 |
| Estimated completion | 15 May 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Nerivio
Conditions studied
- Migraine in Children — all drugs for Migraine in Children →
Sponsor
Theranica — full company profile →
Who can join
Under 18, any sex, with Migraine in Children. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a retrospective survey-study to assess the accessibility, preference, and frequency of adolescents using Nerivio by itself, in combination with pharmacological medications, or not at all, in the school setting. The study population is prescribed Nerivio users, under the age of 18 years old, who have used the Nerivio device at least once. The study will be conducted electronically, and will include eligibility questions, an electronic informed consent form signed by the parent/legal guardian (e-ICF), an assent form signed by the adolescent patient (e-Assent), and an e-survey relating to the management of headaches due to migraine attacks. Participants will be recruited from Nerivio's userbase and will be compensated for their participation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Patterns, Barriers, and Preferences of Treating Migraine Within the School Setting: A Survey Study of Students.
Hershey AD, Shmuely S, Stark-Inbar A, Asmar Y, et al · · 2024 · PMID 39594861 · DOI 10.3390/children11111286
Verify or expand the search:
- PubMed search for NCT06180577
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nerivio
Trials testing the same drug.
- NCT06976723 — Nerivio Efficacy by Time of Treatment Onset · Phase 4 · completed
- NCT06738056 — Nerivio Long-term Usage in Patients With Migraine · completed
- NCT06138756 — Acute Treatment of Migraine in Pre-Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN) · completed
- NCT05940870 — A Prospective Post-marketing Observational Study Assessing the Safety and Efficacy of Nerivio for Migraine Prevention. · completed
- NCT05769322 — Real World Data Analysis: Impact of High-Frequency REN Treatments As Migraine Preventive Therapy in Adolescence · completed
Other recruiting trials for Migraine in Children
Currently open trials in the same condition.
- NCT06277063 — nVNS for the Prevention and Treatment of Primary Headache · NA · recruiting
- NCT06558578 — Association of Helicobacter Pylori Infection and Migraine · NA · recruiting
- NCT05814497 — Supraspinal Processing of Sensory Aspects of Pain · NA · recruiting
Other Theranica trials
Trials by the same sponsor.
- NCT05523310 — Observational Study to Assess Migraine Prediction Tool · suspended
- NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
- NCT07336420 — Treatment Patterns Among US Veterans Using Remote Electrical Neuromodulation (REN) for Migraine Treatment · Phase 4 · completed
- NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
- NCT06976723 — Nerivio Efficacy by Time of Treatment Onset · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06180577 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Theranica
- Last refreshed: 22 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06180577.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing